1
00:00:02,200 --> 00:00:05,120
Repair begins with a biological response.

2
00:00:05,940 --> 00:00:08,240
Establishing that a treatment improves
recovery

3
00:00:08,240 --> 00:00:10,560
takes a different kind of evidence.

4
00:00:11,480 --> 00:00:16,460
BPC-157 is an experimental peptide

5
00:00:16,460 --> 00:00:18,840
made of fifteen amino acids.

6
00:00:19,920 --> 00:00:22,360
Laboratory and animal studies can suggest
mechanisms.

7
00:00:23,480 --> 00:00:26,840
They cannot, by themselves, establish that

8
00:00:26,840 --> 00:00:29,420
an injured person will recover faster.

9
00:00:29,880 --> 00:00:33,580
In a 2021 report, Lee and Padgett reviewed

10
00:00:33,580 --> 00:00:37,780
seventeen knee-pain patients and reached
sixteen for follow-up.

11
00:00:38,440 --> 00:00:41,940
Twelve had received BPC-157 alone;

12
00:00:42,700 --> 00:00:45,120
eleven reported significant pain
improvement.

13
00:00:46,020 --> 00:00:49,200
Four others received it with thymosin beta
four.

14
00:00:49,940 --> 00:00:53,100
Those reports came from an uncontrolled
study.

15
00:00:53,700 --> 00:00:58,240
Less pain does not demonstrate that tendon
or cartilage has healed.

16
00:00:58,680 --> 00:01:02,500
The digestive tract is another major
research focus.

17
00:01:03,220 --> 00:01:09,560
In rat experiments, BPC-157 reduced
experimentally induced stomach

18
00:01:09,560 --> 00:01:13,100
ulcers and improved healing in some fistula
models.

19
00:01:13,880 --> 00:01:16,220
These are encouraging animal findings.

20
00:01:17,020 --> 00:01:20,380
Human evidence includes a 2005 ulcerative-
colitis

21
00:01:20,380 --> 00:01:23,140
trial reported in a conference abstract.

22
00:01:23,960 --> 00:01:26,180
Fifty-three people were randomized.

23
00:01:26,820 --> 00:01:29,900
Disease-activity scores improved in both
groups.

24
00:01:30,500 --> 00:01:32,600
The between-group estimate was too
uncertain

25
00:01:32,600 --> 00:01:34,860
to establish a benefit over placebo.

26
00:01:35,740 --> 00:01:39,860
The FDA concluded that the available data
were

27
00:01:39,860 --> 00:01:43,240
inadequate to establish efficacy and safety
for that use.

28
00:01:44,100 --> 00:01:47,000
Gastrointestinal promise is a research
lead;

29
00:01:47,580 --> 00:01:50,800
reliable treatment success in people
remains unproven.

30
00:01:51,640 --> 00:01:55,480
The next step is a defined preparation, a
fair comparison,

31
00:01:55,480 --> 00:02:00,560
and consistent measures of symptoms,
function, and tissue change.

32
00:02:01,380 --> 00:02:04,620
Safety also needs adequate follow-up.

33
00:02:04,980 --> 00:02:06,940
World Peptide Foundation.

34
00:02:07,600 --> 00:02:09,140
Peptides in 2.

35
00:02:09,460 --> 00:02:10,860
Every experience matters.